🧬 Engineering the Next Generation of Immune Cell Therapies.
At Immunex Shield, our research is driven by a singular goal: to create a lasting, curative solution for cancer and complex immune disorders by leveraging the native power of the human immune system. We are committed to translational science, rapidly moving high-impact discoveries from the Bench to the Bedside through rigorous scientific inquiry and proprietary technology.
at ImmunexShield
Our Proprietary Technology Platforms
🧪 NextGen NK Cell Activation (The Immunex Shield NK-AMP Platform)
We are moving beyond standard NK cell expansion. Our proprietary platform enhances three critical characteristics of Natural Killer cells:
Enhanced Cytotoxicity: Using novel ex vivo activation protocols to significantly increase the cells’ ability to recognize and kill tumor cells.
Extended Persistence: Genetic and media-based modifications to ensure NK cells remain active and proliferate longer in vivo (in the patient’s body), leading to durable responses.
Allogeneic Potential: Developing universal, “Off-the-Shelf” NK cell products derived from healthy donors, reducing patient-specific manufacturing time and increasing accessibility.
🔬 Multi-Targeted T-Cell Engineering
Our focus in T-cell therapy is tackling the challenge of solid tumors and antigen escape.
Logic-Gated CAR/TCR Constructs: Engineering T-cells with receptors that can recognize multiple tumor antigens simultaneously (dual or multi-CARs) to prevent tumor cells from evolving and escaping treatment.
Immunosuppressive Barrier Resistance: Integrating “armored” technologies that allow our T-cells to function effectively within the hostile, immunosuppressive tumor microenvironment (e.g., resistance to TGF- or other inhibitory cytokines).
💡 Precision Antigen Discovery & Profiling
The key to personalization is knowing exactly what to target.
Integrated Multi-Omics Pipeline: Combining analysis of Tumor Mutation Burden (TMB), circulating tumor cells (CTCs), and the Gut Microbiome to generate a precise, patient-specific profile of targetable tumor antigens.
Novel Epitope Identification: Utilizing advanced computational biology and AI to identify non-traditional, highly specific neoantigens unique to a patient’s malignancy for use in personalized vaccines or cell constructs.
Therapeutic Pipeline: Clinical and Preclinical Programs
| Program / Platform | Stage | Indication(s) | Mechanism of Action |
|---|---|---|---|
| IS-NK-001 (NK-AMP Platform) | Preclinical / IND-enabling | Refractory AML, Lymphoma | Enhanced NK-cell cytotoxicity and persistence |
| IS-TCR-Solid (T-FORCE System) | Discovery / Preclinical | Pancreatic Cancer, NSCLC | Targeting novel solid tumor-specific antigens |
| IS-DC-Auto (Dendritic Cell) | Discovery | Type 1 Diabetes (Autoimmune) | Inducing immune tolerance via regulatory DC vaccine |